Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.
BioSpace

Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data

While participants on a lower dose of Wave Life Sciences’ RNA therapy lost 5.3% total fat at the six-month mark, those ...

Biogen stock pops after FDA approves new high-dose Spinraza for spinal muscular atrophy

Biogen Inc. BIIB shares are up on Monday following the FDA’s approval of a new high-dose regimen for Spinraza (nusinersen), a ...
24/7 Wall St.

Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?

Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its ...

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 ...